SCHEMBL2932045

SCHEMBL2932045

O=Cc1ccc(OCc2ccccc2)c(C(=O)N2CCN(c3ccccc3)CC2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.50
TSHR P16473 5/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
USP2 O75604 2/20 0.50
ALOX15 P16050 1/20 0.48
KDM4E B2RXH2 2/20 0.48
POLB P06746 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
GRM5 P41594 1/20 0.48
MAPT P10636 5/20 0.47
LMNA P02545 4/20 0.47
TP53 P04637 2/20 0.47
HSD17B10 Q99714 2/20 0.47
SLC6A9 P48067 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
RAB9A P51151 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
GAA P10253 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2932586 0.88 HSD17B10 (0.58) ALDH1A1TSHRMEN1KMT2AKDM4E
SCHEMBL2932522 0.83 CYP2C9 (0.55) MEN1KMT2ALMNASMN1; SMN2GAA
SCHEMBL1648045 0.78 ALDH1A1 (0.73) ALDH1A1KDM4EPOLBL3MBTL1LMNA
SCHEMBL2932472 0.78 ADAMTS5 (0.70)
SCHEMBL2928206 0.78 DRD4 (0.48) ALDH1A1TSHRMEN1KMT2AALOX15
SCHEMBL1315281 0.76 ALDH1A1 (0.59) ALDH1A1MEN1KMT2AKDM4EPOLB
SCHEMBL6170061 0.76 ALDH1A1 (0.59) ALDH1A1KMT2AKDM4EPOLBL3MBTL1
SCHEMBL852240 0.75 ALDH1A1 (0.59) ALDH1A1KDM4EPOLBL3MBTL1MAPT
SCHEMBL4481337 0.74 SMN1; SMN2 (0.58) ALDH1A1TSHRMEN1KMT2AUSP2
SCHEMBL23201166 0.73 CA1 (0.58) MEN1KMT2AKDM4EGRM5MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1656361-B1 PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS HOFFMANN LA ROCHE (CH) 2008-01-02 EP claimed
EP-3199156-A1 USE OF GLYCINE TRANSPORTER 1 ANTAGONISTS AS CENTRAL NERVOUS ANALGESICS Heinrich-Heine-Universität Düsseldorf (DE) 2017-08-02 EP disclosed
EP-1313731-B1 THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT UCB SA (BE) 2010-09-29 EP disclosed
EP-1656361-B1 PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS HOFFMANN LA ROCHE (CH) 2008-01-02 EP disclosed
US-6740670-B2 SUCH AS 5-(((3-(N-METHYL-N-PHENYLAMINO)CARBONYL-4-(PHENYL-METHOXY)) -PHENYL)METHYLENE)-4-OXO-2-THIOXO-3-THIAZOLIDINE-ACETIC ACID OXFORD GLYCOSCIENCES (UK) LTD. (GB) 2004-05-25 US disclosed
US-20030216453-A1 Thiazolidine derivatives and its use as antifungal agent OXFORD GLYCOSCIENCES (UK) LTD (GB) 2003-11-20 US disclosed
EP-1313731-A1 THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT Oxford GlycoSciences (UK) Limited (GB) 2003-05-28 EP disclosed
WO-2002022612-A1 THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT OXFORD GLYCOSCIENCES (UK) LIMITED (GB) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216453-A1 Thiazolidine derivatives and its use as antifungal agent CYP3A7, TAS2R7, OXSR1 ALDH1A1 2527/4885TSHR 220/4885MEN1 1832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.